Steven W. Ryder

Steve Ryder received his M.D. from Mt. Sinai School of Medicine in 1974, and he completed his clinical training and board certification in internal medicine (1975-77) and endocrinology-metabolism (1977-79) at the State University of New York (SUNY) at Stony Brook. His research training in endocrinology was undertaken with Dr. Rosalyn Yalow in the Berson Laboratory of the Bronx Veteran's Administration Medical Center (1979-81). While at the Berson Laboratory, his research interests focused on the immunochemical characterization of cholecystokinin and other CNS peptides. In 1982, he joined Ayerst Laboratories (New York, NY) as an Assistant Director of Clinical Research, assuming responsibility for CNS and endocrine/metabolic clinical development. In 1987, he joined Pfizer Central Research (Groton, CT) as Group Director of Clinical Research. During the ensuing 15 years, he has been involved in the clinical development of many Pfizer products and has held positions of increasing responsibility, most recently assuming the position of Senior Vice President and Global Cardiovascular/Metabolism/GI/GU Development Head. In this position, he supervises 5 Full Devlelopment Team Leaders and 2 Therapeutic Area Vice-Presidents at development sites in the U.S. and Europe. His work is based in New London, CT and he lives in [redacted].

Address

Home: [redacted]

Work: Pfizer Global Research & Development
50 Pequot Avenue, New London, CT
[redacted]

Professional (Industry)

Sr. Vice President and Global Cardiovascular/ Metabolic/GI/GU Development Head (2003)	Pfizer Global Research and Development New London, CT
Sr. Vice President and Director, Worldwide Clinical Development (2000)	Pfizer Global Research and Development New London, CT
Sr. Vice President, U.S. Clin Research (1997) Vice President, U.S. Clinical Operations (1995) Executive Director, Clinical Research (1992) Group Director, Clinical Research (1987)	Pfizer Central Research Groton, CT
Senior Director, Clinical Research (1986) Director, Clinical Research (1984) Associate Director, Clinical Research (1983) Assistant Director, Clinical Research (1982)	Ayerst Laboratories New York, NY

Professional (Non-Industry)

Associate Investigator (1979)	Solomon A. Berson Research Laboratory VA Medical Center, Bronx, NY
Instructor, Department of Medicine (1979)	Albert Einstein College of Medicine Bronx, NY
Assistant Attending Physician (1979) Department of Medicine	Montefiore Hospital Medical Center Bronx, NY
Staff Physician (1981) Department of Medicine	University Hospital Health Science Center Stonybrook, NY
Laboratory Director (1981)	Suffolk Endocrine Laboratory Bay Shore, NY

S. W. Ryder, M.D.

Special Positions

Member, Board of Directors, and Chair of the Joint Medical Committee (2002-)
Gaylord Hospital, Wallingford, CT
Chairman – Clinical Leadership Committee (2003-)
Pharmaceutical Research and Manufacturers of America (PhRMA)
Co-Chair – Clinical Hepatotoxicity Working Group (2001-)
PhRMA /FDA/American Association for the Study of Liver Diseases

Personal

Born:

Education

M.D. (1974) Mount Sinai School of Medicine (1972-74)
Albany Medical College (1970-72)
Rensselaer Polytechnic Institute (1968-72)

Training

Internal Medicine (1974-77) VA Medical Center, Northport, NY
(SUNY Stonybrook School of Medicine)
Endocrinology VA Medical Center, Northport, NY
(SUNY Stonybrook School of Medicine)

Certification

American Board of Internal Medicine (1977)
American Board of Internal Medicine (Endocrinology and Metabolism) (1979)

Professional License

Connecticut (1987)

Awards (Professional)

Pfizer Central Research Achievement Award (1999)

Awards (Medical School)

The 2nd Daggett Prize in Anatomy
Merck Manual Award in Physiology
Mosby Scholarship Award (Most Commendable Summer Research Project)
Albany Medical College Student Research Award
Alan F. Guttmacher (Clinical Obstetrics and Gynecology)

Membership

American College of Physicians (Fellow)
Endocrine Society
American Society for Clinical Pharmacology and Therapeutics
American Association for the Advancement of Science
American Academy of Pharmaceutical Physicians

Continuing Education

The Executive Forum (1998, 1999)

Program for Advanced Training in Biomedical Research Management (1991)

Seminar for Managers of Industrial Research (1988)

Presentations

S. W. Ryder, M.D.

1. E. Straus, S. W. Ryder, J. Eng, R. S. Yalow. Immunochemical Studies Relating to Cholecystokinin in Brain and Gut. The Laurentian Hormone Conference - 1980.
2. S. Ryder. "Endocrinology of Cancer", Family Practice Review Course Department of Family Practice, SUNY Stonybrook School of Medicine - 1981.
3. S. Ryder. Protein and Polypeptide Drugs: Overview 1983. The International Industrial Pharmaceutical Conferences (sponsored by Univ. of Tx, Austin) - 1983.
4. D. Dvornik, R. Gonzalez, D. Hicks T. Smith, S. Ryder, J. F. Mullane, P. Raskin, J. Rosenstock, P. Challis, J. Caro and W. Fore. Effects of tolrestat on RBC sorbitol levels in subjects with diabetes mellitus. X11 Congress, International Diabetes Federation, Madrid – 1985
5. P. Raskin, J. Rosenstock, P. Challis, S. Ryder, J. F. Mullane, R. Gonzalez, D. Hicks, T. Smith, D. Dvornik. Effect of tolrestat on RBC sorbitol levels in diabetic subjects. American Diabetes Association, Baltimore - 1985.
6. D. J. Weidler, D. C. Garg, M. Marino, M. Jallad, S.W. Ryder, J. Millen, D. Dvornik. The effects of tolrestat administered once or twice daily on the sorbitol concentration in the red blood cells of persons with diabetes mellitus. Third World Conference on Clinical Pharmacology and therapeutics, Stockholm, Sweden - 1986.
7. D. G. Shand and the Tolrestat Painful Neuropathy Group. The effects to tolrestat, a new aldose reductase inhibitor, on nerve conduction and painful symptoms in diabetic neuropathy. British Diabetic Association, Cardiff, United Kingdom - 1986.
8. A.J.M. Boulton and the Tolrestat in Neuropathy Study Group. The effects and safety of tolrestat, a new aldose reductase inhibitor, in symptomatic diabetic neuropathy: report of a one year multi-centre trial. British Diabetic Association, Cardiff, United Kingdom - 1986.
9. A.J.M. Boulton and the Tolrestat in Neuropathy Study Group. Effects of tolrestat, a new aldose reductase inhibitor, on nerve conduction and paresthetic symptoms in diabetic neuropathy. European Association for the Study of Diabetes, Rome, Italy - 1986.
10. S. Ryder and the Tolrestat in Painful Neuropathy Study Group. Objective (nerve conduction) and subjective (painful symptom) improvement in diabetic neuropathy following administration of tolrestat a new aldose reductase inhibitor. European Association for the Study of Diabetes, Rome, Italy - 1986.
11. D. J. Weidler, D. C. Garg, M. Marino, M. Jallad, S. W. Ryder, J. Millen, D. Dvornik. The effects of tolrestat administered once or twice daily on the sorbitol concentration in the red blood cells of persons with diabetes mellitus. American College of Clinical Pharmacology, Philadelphia - 1986.
12. S. Ryder, D. G. Shand, J. F. Mullane. Possible efficacy of tolrestat (T), a novel aldose reductase inhibitor, in the treatment of diabetic hypertension. American Society for Clinical Pharmacology and Therapeutics, Orlando - 1987.
13. S. Ryder, Sponsor's Presentation of 33rd Psychopharmacological Drugs Advisory Committee (November 19th, 1990) (NDA 19,839 - Sertraline).
14. S. Ryder, Sponsor's Presentation (Hypertension and Safety) of June 7th, 1991, Cardio Renal Drugs Advisory Committee (NDA 19,787 - Amlodipine).
15. S. Ryder, The Role of Biometricians in the Drug Development Process: Clinical Perspective from Industry Viewpoint. American Statistical Association, Raleigh, NC - 1995.
16. S. Ryder. Re-Engineering Process to Accelerate Clinical Development – the Industry Perspective. Drug Information Association 31st Annual Meeting, Orlando, FL - 1995.
17. S. Ryder, Managing Change in Global Drug Development. The Conference Board: Conference on Managing Change, New York, NY - 1998
18. S. Ryder, Sponsor's Presentation (Overview and Q&A) of January 28th, 1999, Cardio Renal Drugs Advisory Committee (NDA 20,931 - Dofetilide).
19. S. Ryder, Global Drug Development for Diabetic Complications. Drug Information Association 35th Annual Meeting, Baltimore, MD - 1999.

Publications

S. W. Ryder, M.D.

1. S. Ryder, G. Murthy Gollapudi, A. Varma. The relationship of serum T4 and T3 to TSH in primary hypothyroidism. Archives of Internal Medicine 140: 1290-191, 1980.
2. S. Ryder, G. Murthy Gollapudi, D. Ryder. Morphine sulfate inhibits insulin release from isolated, superfused rat pancreatic islets. Hormone and Metabolic Research 12: 412-413, 1980.
3. S. Ryder, E. Straus, R. S. Yalow. Further characterization of brain cholecystokinin-converting enzymes. Proceedings of the National academy of Sciences (USA) 77: 3669-71, 1980.
4. S. Ryder, J. Eng, E.Straus, R. S. Yalow. Alkaline extraction of cholecystokinin- immunoreactivity from rat brain. Biochemical and Biophysical Research Communications 94: 704-709, 1980.
5. E. Straus, S. W. Ryder, J. Eng, R. S. Yalow. Immunochemical studies relating to cholecystokinin in brain and gut. Recent Progress in Hormone Research 37: 447-475, 1981.
6. S. W. Ryder, J. Eng. Radioimmunoassay of leucine-enkephalin-like-substance in human and canine plasma. Journal of Clinical Endocrinology and Metabolism 52: 367-369, 1981.
7. S. Ryder, J. Eng, E. Straus, R. S. Yalow. Alkaline extraction and characterization of cholecystokinin-immunoreactivity from rat gut. Gastroenterology 81: 267-275, 1981.
8. S. Ryder, E. Straus, C. S. Lieber, R. S. Yalow. Cholecystokinin and enkephalin levels following ethanol administration in rats. Peptides 2: 223-226, 1981.
9. S. Ryder, J. Eng, E. Straus, R. S. Yalow. Extraction and immunochemical characterization of cholecystokinin-like peptides in pig and rat brain. Proceedings of the National Academy of Sciences (USA) 78: 3892-3896, 1981.
10. E. Straus, S. Ryder, J. Eng, R. S. Yalow. Nature of Immunoreactive CCK in rat and pig brain. Peptides 2 (Suppl 2): 89-92, 1981.
11. S. Ryder, I. Salom, G. Jacob, M. Sanda, J. Huth. Etodolac (ULTRADOL ™): the safety profile of a new structurally-novel nonsteroidal anti-inflammatory drug. Current Therapeutic Research 33: 948-965, 1983.
12. B. Zaim, M. Kraml, D. Dvornik, S. Ryder, J. F. Mullane. INDERAL® LA: comparison of the profiles of plasma drug concentration/time curves produced in man by propranolol hydrochloride long-acting (80 and 160 mg) and atenolol (50 and 100 mg) Current Therapeutic Research 35: 896-904, 1984.
13. D. R. Hicks, M. Kraml, M. N. Cayen, J. Dubuc, S. Ryder, D. Dvornik. Tolrestat kinetics. Clinical Pharmacology and Therapeutics 36: 493-499, 1984.
14. P. Raskin, J. Rosenstock, P. Challis, S. Ryder, J. F. Mullane, R. Gonzalez, D. Hicks, T. Smith, D. Dvornik. Effect of tolrestat on red blood cell sorbitol levels in diabetic subjects. Clinical Pharmacology and Therapeutics 38: 625-630, 1985.
15. S. Ryder, B. Sarokhan, D. G. Shand, J. F. Mullane. Human safety profile of tolrestat: an aldose reductase inhibitor. Drug Development Research 11: 131-143, 1987.
16. A. J. M. Boulton, S. Levin and J. Comstock (for the North American Tolrestat in Neuropathy Research Group). A multicentre trial of the aldose-reductase inhibitor, tolrestat, in patients with symptomatic diabetic neuropathy. Diabetologia 33: 431-437, 1990.

Abstracts

1. S.W. Ryder (introduced by R. S. Yalow). Transitory inhibition by morphine sulfate of glucose stimulated insulin release from rat pancreatic islets. Diabetes 29 (Suppl 2): 111A, 1980.
2. S. Ryder, J. Eng, E. Straus, R. S. Yalow. Characterization of big-and small-cholecystokinin-like peptides (iCCK) in pig and rat brain. Endocrinology 108 (Suppl): 275, 1981.
3. P. Raskin, J. Rosenstock, P. Challis, S. Ryder, J. F. Mullane, R. Gonzalez, D. Hicks, T. Smith, D. Dvornik. Effect of tolrestat on RBC sorbitol levels in diabetic subjects. Diabetes 34 (Suppl 1): 7A, 1985.
4. L. Koglin, C. Clark, S. Ryder, J. F. Mullane. The results of long-term open-label administration of ALREDASE™ in the treatment of diabetic neuropathy. Diabetes 34 (Suppl 1): 202A, 1985.
5. D. Dvornik, R. Gonzalez, D. Hicks, T. Smith, S. Ryder, J. f. Mullane, P. Raskin, J. Rosenstock, P. Challis, J. Caro and W. Fore. Effects of tolrestat on RBC sorbitol levels in subjects with diabetes mellitus. Diabetes Research and Clinical Practice (Suppl 1): S-146, 1985.

6. L. Koglin, J. Kincaid, N. Fineberg, C. Clark, J. Hauptman, and S. Ryder. the aldose reductase inhibitor tolrestat increase peripheral nerve conduction velocities and decreases neuropathic pain in patients with symptomatic, peripheral diabetic neuropathy. Diabetes 35 (Suppl 1): 118A, 1986.
7. A. J. M. Boulton and the Tolrestat in Neuropathy Study Group. Effects of tolrestat, a new aldose. reductase inhibitor, on nerve conduction and paresthetic symptoms in diabetic neuropathy Diabetologia 29: 521A, 1986.
8. S. Ryder and the Tolrestat in Painful Neuropathy Study Group. Objective (nerve conduction) and subjective (painful symptom) improvement in diabetic neuropathy following administration of tolrestat, a new aldose reductase inhibitor. Diabetologia 29: 588, 1986.
9. D. J. Weidler, D. C. Garg, M. R. Marino, N. S. Jallad, S. W. Ryder, J. Millen, D. Dvornik. The effects of tolrestat administered once or twice daily on the sorbitol concentration in the red blood cells of persons with diabetes mellitus. J. Clin. Pharmacol. 26: 552, 1986.
10. S. Ryder, D. G. Shand, J. F. Mullane. Possible efficacy of tolrestat (T), a novel aldose reductase inhibitor, in the treatment of diabetic hypertension. Clinical Pharmacology and Therapeutics 41: 217, 1987.

Letters

1. S. Shetty, G. Murthy, W. Shreeve, A. Nawaz, S. Ryder. Hyperthyroidism after pyelography. New England Journal of Medicine 291: 682, 1974.
2. S. W. Ryder, J. F. Mullane. Gastric mucosa in portal hypertension. Gastroenterology 87: 1404-1407, 1984.

Patents

1. U.S. Patent No. 4,701,467. Tolrestat as antihypertensive agent. S. W. Ryder, D. G. Shand, and J. F. Mullane. October 20, 1987.
2. U.S. Patent No. 4,716,177. Tolrestat for inhibition of weight gain. S. W. Ryder, D. G. Shand, and J. F. Mullane. December 29, 1987.
3. European Patent No. 87303095.1. Tolrestat as antihypertensive agent. S. W. Ryder, D. G. Shand, and J. F. Mullane. June 19, 1987.